JP7594686B2 - ベータコロナウイルス弱毒株 - Google Patents

ベータコロナウイルス弱毒株 Download PDF

Info

Publication number
JP7594686B2
JP7594686B2 JP2023558098A JP2023558098A JP7594686B2 JP 7594686 B2 JP7594686 B2 JP 7594686B2 JP 2023558098 A JP2023558098 A JP 2023558098A JP 2023558098 A JP2023558098 A JP 2023558098A JP 7594686 B2 JP7594686 B2 JP 7594686B2
Authority
JP
Japan
Prior art keywords
strain
mutation
amino acid
temperature
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023558098A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023080246A5 (de
JPWO2023080246A1 (de
Inventor
志郎 竹河
博貴 蝦名
真弥 岡村
秋穂 吉田（柏原）
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Microbial Diseases of Osaka University BIKEN
Original Assignee
Research Foundation for Microbial Diseases of Osaka University BIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Microbial Diseases of Osaka University BIKEN filed Critical Research Foundation for Microbial Diseases of Osaka University BIKEN
Publication of JPWO2023080246A1 publication Critical patent/JPWO2023080246A1/ja
Publication of JPWO2023080246A5 publication Critical patent/JPWO2023080246A5/ja
Priority to JP2024175879A priority Critical patent/JP2025005450A/ja
Application granted granted Critical
Publication of JP7594686B2 publication Critical patent/JP7594686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023558098A 2021-11-08 2022-11-07 ベータコロナウイルス弱毒株 Active JP7594686B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024175879A JP2025005450A (ja) 2021-11-08 2024-10-07 ベータコロナウイルス弱毒株

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021182051 2021-11-08
JP2021182051 2021-11-08
JP2022133080 2022-08-24
JP2022133080 2022-08-24
PCT/JP2022/041445 WO2023080246A1 (ja) 2021-11-08 2022-11-07 ベータコロナウイルス弱毒株

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024175879A Division JP2025005450A (ja) 2021-11-08 2024-10-07 ベータコロナウイルス弱毒株

Publications (3)

Publication Number Publication Date
JPWO2023080246A1 JPWO2023080246A1 (de) 2023-05-11
JPWO2023080246A5 JPWO2023080246A5 (de) 2024-07-12
JP7594686B2 true JP7594686B2 (ja) 2024-12-04

Family

ID=86241618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023558098A Active JP7594686B2 (ja) 2021-11-08 2022-11-07 ベータコロナウイルス弱毒株
JP2024175879A Pending JP2025005450A (ja) 2021-11-08 2024-10-07 ベータコロナウイルス弱毒株

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024175879A Pending JP2025005450A (ja) 2021-11-08 2024-10-07 ベータコロナウイルス弱毒株

Country Status (7)

Country Link
US (1) US20250002871A1 (de)
EP (1) EP4431599A4 (de)
JP (2) JP7594686B2 (de)
KR (1) KR20240099257A (de)
AU (1) AU2022380191A1 (de)
TW (1) TW202334404A (de)
WO (1) WO2023080246A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102748970B1 (ko) * 2024-05-02 2024-12-31 전북대학교 산학협력단 N 유전자의 전사 억제 및 nsp1 단백질의 돌연변이를 포함하는 약독화된 SARS-CoV-2 백신주 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021361384A1 (en) * 2020-10-14 2023-06-01 The Research Foundation For Microbial Diseases Of Osaka University Temperature-sensitive betacoronavirus strain and vaccine

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DENG X et al.，Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the Macrodomain a，Journal of Virology，2019年，Vol.93, No.12 e02140-18，p.1-16
FLOWER TG et al.，Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein，PNAS，2020年12月23日，Vol.118, No.2 e2021785118，p.1-6
JOHNSON BA et al.，Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis，Nature，Vol.591，p.293-299
OKAMURA S and EBINA H，Could live attenuated vaccines better control COVID-19?，Vaccine，2021年08月11日，Vol.39，p.5719-5726
OKAMURA S at al.，Live attenuated SARS-CoV-2 vaccine candidate: Protective immunity without serious lung lesions in Sy，bioRixiv，2021年02月16日
SAWICKI SG et al.，Functional and genetic analysis of coronavirus replicase-transcriptase proteins，PloS Pathogens，Vol.1, No.4, e39，p.310-322
SEO SH et al.，Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from，Vaccines，2020年10月03日，Vol.8, No.4, 584，p.1-17
岡村真弥ほか，弱毒生ワクチンの開発を目指したＳＡＲＳ－ＣｏＶ－２低温馴化株の分離と解析，日本薬学会年会要旨集，2021年03月05日，Vol.141，27V07-pm15

Also Published As

Publication number Publication date
KR20240099257A (ko) 2024-06-28
WO2023080246A1 (ja) 2023-05-11
AU2022380191A2 (en) 2024-06-13
EP4431599A1 (de) 2024-09-18
US20250002871A1 (en) 2025-01-02
AU2022380191A1 (en) 2024-06-06
JP2025005450A (ja) 2025-01-16
JPWO2023080246A1 (de) 2023-05-11
EP4431599A4 (de) 2026-03-18
TW202334404A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
JP6368725B2 (ja) 豚ヘルペスウイルス遺伝子欠失株、ワクチン組成物及びその製造方法と応用
WO2022080414A1 (ja) ベータコロナウイルス温度感受性株及びワクチン
WO2024197167A1 (en) A cold-adapted, live attenuated sars-cov-2 vaccine
JP2025005450A (ja) ベータコロナウイルス弱毒株
TWI704225B (zh) 豬繁殖與呼吸綜合症疫苗病毒
JP2023070661A (ja) ベータコロナウイルスの不活化抗原
CN118660957A (zh) β冠状病毒减毒株
TWI912376B (zh) 減毒之豬流行性下痢病毒
CN116583604A (zh) β冠状病毒温度敏感性株和疫苗
US20240285752A1 (en) Attenuated Porcine Epidemic Diarrhea Virus
RU2787596C9 (ru) Вакцина к вирусу свиного гриппа a
RU2787596C2 (ru) Вакцина к вирусу свиного гриппа a
김새진 Preclinical evaluation of a live avian metapneumovirus subtype B vaccine strain with cross-protective efficacy in chickens
KR20120134015A (ko) 돼지 생식기 호흡기 증후군 바이러스 유사입자 및 이를 이용한 백신
TW202523684A (zh) 用於控制口蹄疫的疫苗組成物及方法
Njenga A Wild Goose Metapneumovirus Containing a Large Attachment Glycoprotein Is Avirulent but Immunoprotective in Domestic Turkeys

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240607

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241122

R150 Certificate of patent or registration of utility model

Ref document number: 7594686

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150